Losartan Effects on Emphysema Progression — LEEP  

Emphysema Clinical Trial

Official title: Losartan Effects on Emphysema Progression

Status Completed

Clinical Trial Summary

A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan on the progression of emphysema as measured by quantitative HRCT compared to placebo

.

Clinical Trial Description

This is a trial designed to test if a treatment, losartan, may decrease the progression of Chronic Obstructive Pulmonary Disease (COPD). Losartan is an angiotensin receptor blocking agent, commonly used as an antihypertensive agent, which has been shown to alter cardiac remodeling after myocardial infarction and renovascular remodeling in diabetes-mellitus. In this trial participants with mild to severe COPD, with Computed Tomography (CT) evidence of emphysema (5-35% of voxels with < -950 Hounsfield Units), will be randomly assigned to receive 100mg/day of losartan or placebo for 48 weeks. The primary outcome measure will be the rate of progression of emphysema, quantified as the percent of lung voxels with a density less than -950 HU as measured by High Resolution CT (HRCT, from baseline to 48 weeks. ;

Related Conditions & MeSH terms

• Emphysema
• Pulmonary Emphysema

• NCT number: NCT02696564
• Study type: Interventional
• Source: JHSPH Center for Clinical Trials
• Status: Completed
• Phase: Phase 4
• Start date: May 23, 2017
• Completion date: June 30, 2021